← Back to patent-cliff list
LU-177-SSTR- PNT-2003
Tier C — Watch / tradeLU-177-SSTR- PNT-2003
Point Biopharma Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：SSTR
Indications (approved)：Neuroendocrine tumour
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LU-177-SSTR- PNT-2003?
Approved indications include: Neuroendocrine tumour.
When does the LU-177-SSTR- PNT-2003 patent expire?
No public expiry year is available for LU-177-SSTR- PNT-2003 yet; this page updates once verified.
How do I get a quote for LU-177-SSTR- PNT-2003 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06